Anika Therapeutics Inc. (NASDAQ:ANIK) Director Joseph I. Bower sold 540 shares of the company’s stock in a transaction dated Wednesday, November 9th. The shares were sold at an average price of $43.39, for a total transaction of $23,430.60. Following the transaction, the director now directly owns 38,513 shares of the company’s stock, valued at $1,671,079.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Anika Therapeutics Inc. (NASDAQ:ANIK) opened at 45.56 on Monday. The company’s 50 day moving average is $45.09 and its 200 day moving average is $47.74. The stock has a market cap of $666.22 million, a PE ratio of 19.55 and a beta of 1.68. Anika Therapeutics Inc. has a 12 month low of $35.07 and a 12 month high of $54.96.

Anika Therapeutics (NASDAQ:ANIK) last posted its earnings results on Wednesday, October 26th. The company reported $0.59 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.47 by $0.12. The company earned $25.79 million during the quarter, compared to analysts’ expectations of $26.60 million. Anika Therapeutics had a net margin of 33.64% and a return on equity of 17.21%. Anika Therapeutics’s quarterly revenue was up 8.9% on a year-over-year basis. During the same period last year, the company posted $0.55 earnings per share. On average, analysts anticipate that Anika Therapeutics Inc. will post $2.15 EPS for the current fiscal year.

Separately, Zacks Investment Research raised shares of Anika Therapeutics from a “hold” rating to a “strong-buy” rating and set a $49.00 price objective for the company in a research note on Monday, October 31st.

Institutional investors have recently bought and sold shares of the stock. Municipal Employees Retirement System of Michigan boosted its position in Anika Therapeutics by 1.6% in the third quarter. Municipal Employees Retirement System of Michigan now owns 3,180 shares of the company’s stock valued at $152,000 after buying an additional 50 shares during the last quarter. American International Group Inc. boosted its position in Anika Therapeutics by 0.6% in the third quarter. American International Group Inc. now owns 10,594 shares of the company’s stock valued at $507,000 after buying an additional 67 shares during the last quarter. Smith Asset Management Group LP boosted its position in Anika Therapeutics by 2.1% in the third quarter. Smith Asset Management Group LP now owns 6,460 shares of the company’s stock valued at $309,000 after buying an additional 130 shares during the last quarter. Guggenheim Capital LLC boosted its position in Anika Therapeutics by 2.7% in the second quarter. Guggenheim Capital LLC now owns 5,430 shares of the company’s stock valued at $291,000 after buying an additional 141 shares during the last quarter. Finally, Capstone Asset Management Co. boosted its position in Anika Therapeutics by 3.2% in the second quarter. Capstone Asset Management Co. now owns 4,830 shares of the company’s stock valued at $259,000 after buying an additional 150 shares during the last quarter. 76.70% of the stock is owned by institutional investors.

Anika Therapeutics Company Profile

Anika Therapeutics, Inc is an orthopedic medicines company. The Company offers therapeutic pain management solutions. It is engaged in developing, manufacturing and commercializing approximately 20 products based on its hyaluronic acid (HA) technology. It orthopedic medicine portfolio consists of marketed (ORTHOVISC and MONOVISC) and pipeline (CINGAL and HYALOFAST in the United States) products to alleviate pain and restore joint function by replenishing depleted HA and aiding cartilage repair and regeneration.

5 Day Chart for NASDAQ:ANIK

Receive News & Stock Ratings for Anika Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anika Therapeutics Inc. and related stocks with our FREE daily email newsletter.